{"id":"valsartan-valsartan-hydrochlorothiazide","safety":{"commonSideEffects":[{"rate":"7–10","effect":"Dizziness"},{"rate":"2–5","effect":"Fatigue"},{"rate":"2–4","effect":"Hyperkalemia"},{"rate":"5–10","effect":"Hypokalemia (with HCTZ component)"},{"rate":"1–2","effect":"Cough"},{"rate":"5–8","effect":"Headache"},{"rate":"3–5","effect":"Hypotension"}]},"_chembl":{"chemblId":"CHEMBL1069","moleculeType":"Small molecule","molecularWeight":"435.53"},"_dailymed":{"setId":"d76a0419-05ee-437e-884c-65807aea9569","title":"DIOVAN HCT (VALSARTAN AND HYDROCHLOROTHIAZIDE) TABLET, FILM COATED [NOVARTIS PHARMACEUTICALS CORPORATION]"},"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Valsartan is an angiotensin II receptor blocker (ARB) that selectively antagonizes the AT1 receptor, preventing angiotensin II-mediated vasoconstriction and aldosterone release, thereby reducing blood pressure and cardiac workload. Hydrochlorothiazide is a thiazide diuretic that inhibits sodium reabsorption in the distal convoluted tubule, promoting urinary sodium and water loss to further lower blood pressure. The combination provides complementary antihypertensive effects.","oneSentence":"Valsartan blocks angiotensin II receptors to relax blood vessels and lower blood pressure; the combination with hydrochlorothiazide adds a diuretic to enhance sodium and water excretion.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:53:45.685Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hypertension"},{"name":"Heart failure with reduced ejection fraction"},{"name":"Post-myocardial infarction with left ventricular dysfunction"}]},"trialDetails":[{"nctId":"NCT07458880","phase":"NA","title":"Triple Antihypertensive Medication After Intracerebral Hemorrhage for Blood Pressure Control","status":"RECRUITING","sponsor":"The University of Hong Kong","startDate":"2026-03-01","conditions":"Intracerebral Hemorrhage","enrollment":140},{"nctId":"NCT05609513","phase":"NA","title":"Integration of Hypertension Management in HIV Care in Uganda","status":"COMPLETED","sponsor":"Infectious Diseases Research Collaboration, Uganda","startDate":"2023-02-06","conditions":"HIV/AIDS, Hypertension","enrollment":87421},{"nctId":"NCT05920005","phase":"PHASE3","title":"Candesartan Cilexetil + Chlorthalidone + Amlodipine Versus Exforge HCT®️ for Systemic Arterial Hypertension","status":"COMPLETED","sponsor":"Hospital Israelita Albert Einstein","startDate":"2023-08-22","conditions":"Hypertension","enrollment":702},{"nctId":"NCT03553810","phase":"PHASE2","title":"Role of ARNi in Ventricular Remodeling in Hypertensive LVH","status":"COMPLETED","sponsor":"National Heart Centre Singapore","startDate":"2019-04-12","conditions":"Hypertensive Heart Disease","enrollment":80},{"nctId":"NCT00546754","phase":"PHASE3","title":"BP-EASE -Effectiveness of Losartan 50 mg/Hydrochlorothiazide (HCTZ) 12.5 mg Versus Valsartan 80 mg/HCTZ 12.5 mg Titrated as Needed in Patients With Essential Hypertension Not Controlled on Monotherapy (0954A-333)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2007-05-01","conditions":"Hypertension","enrollment":808},{"nctId":"NCT06395194","phase":"PHASE3","title":"Effects of Valsartan vs Amlodipine and Low BP on Kidney Outcomes in Essential Hypertension","status":"COMPLETED","sponsor":"Oslo University Hospital","startDate":"1997-09-27","conditions":"Essential Hypertension","enrollment":15313},{"nctId":"NCT00171015","phase":"PHASE3","title":"VALORY Study of Valsartan/Hydrochlorizide for Patients Who do Not Respond Adequately to Olmesartan Medoxomil","status":"COMPLETED","sponsor":"Novartis","startDate":"2004-12","conditions":"Hypertension","enrollment":212},{"nctId":"NCT00171782","phase":"PHASE4","title":"Hypertension and Cardiovascular Risk Factors","status":"COMPLETED","sponsor":"Novartis","startDate":"2004-02","conditions":"HYPERTENSION","enrollment":76},{"nctId":"NCT05545059","phase":"PHASE3","title":"Effects and Safety of Sacubitril/Valsartan on Refractory Hypertension","status":"UNKNOWN","sponsor":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","startDate":"2022-09-24","conditions":"Resistant Hypertension","enrollment":138},{"nctId":"NCT04467931","phase":"","title":"ACEI or ARB and COVID-19 Severity and Mortality in US Veterans","status":"COMPLETED","sponsor":"University of Utah","startDate":"2020-01-19","conditions":"Hypertension, COVID","enrollment":22213},{"nctId":"NCT00523744","phase":"PHASE3","title":"Efficacy and Safety of Valsartan and Amlodipine (± HCTZ) in Adults With Moderate, Inadequately Controlled Hypertension","status":"COMPLETED","sponsor":"Novartis","startDate":"2007-07","conditions":"Hypertension","enrollment":257},{"nctId":"NCT04330300","phase":"PHASE4","title":"Coronavirus (COVID-19) ACEi/ARB Investigation","status":"SUSPENDED","sponsor":"National University of Ireland, Galway, Ireland","startDate":"2020-04-30","conditions":"Hypertension, COVID-19","enrollment":2414},{"nctId":"NCT00219102","phase":"PHASE3","title":"A Clinical Study to Evaluate Safety & Efficacy of the Combination of Aliskiren, Valsartan & Hydrochlorothiazide in Diabetic Hypertensive Nonresponder Patients","status":"COMPLETED","sponsor":"Novartis","startDate":"2005-06","conditions":"Hypertension, Diabetes","enrollment":336},{"nctId":"NCT01245608","phase":"PHASE3","title":"Prevention of Cardiovascular Disease Using a Single PolyPill in an Urban Population - Focus on Liver-Related Variables.","status":"COMPLETED","sponsor":"Tehran University of Medical Sciences","startDate":"2011-10","conditions":"Cardiovascular Diseases","enrollment":2400},{"nctId":"NCT01271985","phase":"PHASE3","title":"Prevention of Cardiovascular Disease in Middle-aged and Elderly Iranians Using a Single PolyPill","status":"COMPLETED","sponsor":"Tehran University of Medical Sciences","startDate":"2011-02","conditions":"Cardiovascular Diseases","enrollment":8410},{"nctId":"NCT00745953","phase":"PHASE4","title":"Regression of Fatty Heart by Valsartan Therapy","status":"WITHDRAWN","sponsor":"University of Texas Southwestern Medical Center","startDate":"2007-08","conditions":"Metabolic Syndrome, Lipotoxicity","enrollment":""},{"nctId":"NCT00168779","phase":"PHASE4","title":"Randomized, Double-Blind, Placebo-Controlled, Forced-Titration, Comparing Telmisartan vs Valsartan. Taken Orally for Eight Weeks in Patients With Stage 1 and Stage 2 Hypertension","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2005-09","conditions":"Hypertension","enrollment":1185},{"nctId":"NCT00250562","phase":"PHASE3","title":"A Study in Chinese Mild to Moderate Hypertensive Patients Comparing the Efficacy of Co-Diovan With Diovan.","status":"COMPLETED","sponsor":"Novartis","startDate":"2005-10","conditions":"Hypertension","enrollment":1171},{"nctId":"NCT00439738","phase":"PHASE4","title":"Safety/Efficacy of Valsartan/Hydrochlorothiazide Combination Compared to Hydrochlorothiazide in Obese Hypertensive Adults","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2006-12","conditions":"Hypertension","enrollment":412},{"nctId":"NCT02433119","phase":"PHASE4","title":"The Efficacy and Safety of OROSARTAN® Versus CODIOVAN® in Patients With Essential Hypertension Uncontrolled With Monotherapy","status":"COMPLETED","sponsor":"Dong-A ST Co., Ltd.","startDate":"2015-03-16","conditions":"Hypertension","enrollment":238},{"nctId":"NCT00821574","phase":"PHASE4","title":"Reducing the Overall Risk Level in Patients Suffering From Metabolic Syndrome","status":"COMPLETED","sponsor":"Novartis","startDate":"2005-07","conditions":"Hypertension, Dyslypidaemia","enrollment":144},{"nctId":"NCT00171574","phase":"PHASE4","title":"Antiproteinuric Effect of Valsartan and Lisinopril","status":"COMPLETED","sponsor":"Novartis","startDate":"2004-11","conditions":"Hypertension, Diabetic Nephropathy","enrollment":124},{"nctId":"NCT00311740","phase":"PHASE3","title":"A Study of VAH631 in Patients With Essential Hypertension (Factorial Study)","status":"COMPLETED","sponsor":"Novartis","startDate":"2006-03","conditions":"Hypertension","enrollment":582},{"nctId":"NCT00171132","phase":"PHASE4","title":"VALENCE: Valsartan Versus Atenolol on Exercise Capacity in Hypertensive Overweight Postmenopausal Women","status":"COMPLETED","sponsor":"Novartis","startDate":"2004-08","conditions":"Hypertension","enrollment":64},{"nctId":"NCT00000620","phase":"PHASE3","title":"Action to Control Cardiovascular Risk in Diabetes (ACCORD)","status":"COMPLETED","sponsor":"National Heart, Lung, and Blood Institute (NHLBI)","startDate":"1999-09","conditions":"Atherosclerosis, Cardiovascular Diseases, Hypercholesterolemia","enrollment":10251},{"nctId":"NCT00170937","phase":"PHASE4","title":"A 16 Week Study to Evaluate the Effect on Insulin Sensitivity of Valsartan (320 mg) and Hydrochlorothiazide (25 mg) Combined and Alone, in Patients With Metabolic Syndrome","status":"COMPLETED","sponsor":"Novartis","startDate":"2004-11","conditions":"METABOLIC SYNDROME, HYPERTENSION, PRE-HYPERTENSION","enrollment":507},{"nctId":"NCT00360178","phase":"PHASE3","title":"Efficacy and Safety of Valsartan Plus Hydrochlorothiazide in Fixed Dose Combination in Hypertensive Patients Not Controlled by the Free Combination of an Angiotensin Receptor Blocker Plus Hydrochlorothiazide","status":"COMPLETED","sponsor":"Novartis","startDate":"2006-07","conditions":"Hypertension","enrollment":198},{"nctId":"NCT00327145","phase":"PHASE3","title":"A Study to Evaluate the Combination of Valsartan and Amlodipine in Hypertensive Patients Not Controlled on Monotherapy","status":"COMPLETED","sponsor":"Novartis","startDate":"2006-03","conditions":"Hypertension","enrollment":894},{"nctId":"NCT00304226","phase":"PHASE4","title":"Effectiveness of a Valsartan Based Versus an Amlodipine Based Treatment Strategy in naïve Patients With Stage 1 or Stage 2 Hypertension or in Patients Uncontrolled on Current Monotherapy","status":"COMPLETED","sponsor":"Novartis","startDate":"2006-02","conditions":"Hypertension","enrollment":1288},{"nctId":"NCT00666536","phase":"PHASE4","title":"The Effects of Moderate vs. Aggressive Treatment With Valsartan + Amlodipine on Patients With Hypertension Uncontrolled by Angiotensin-Receptor Blocker (Herein, ARB) Monotherapy","status":"COMPLETED","sponsor":"Novartis","startDate":"2008-03","conditions":"Hypertension","enrollment":728},{"nctId":"NCT01365481","phase":"PHASE3","title":"Safety and Tolerability of Valsartan in Children 6 to 17 Years of Age","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2011-08","conditions":"Hypertension, Chronic Kidney Disease","enrollment":150},{"nctId":"NCT01692301","phase":"PHASE2","title":"Study of the Safety and Efficacy of LCZ696 on Arterial Stiffness in Elderly Patients With Hypertension","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2012-12","conditions":"Hypertension","enrollment":454},{"nctId":"NCT01256411","phase":"PHASE2","title":"A Long-term (12 Months) Safety, Tolerability and Efficacy Study of LCZ696 in Patients With Essential Hypertension","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2010-11","conditions":"Essential Hypertension","enrollment":341},{"nctId":"NCT01819220","phase":"PHASE4","title":"Randomized, Open Labeled Clinical Trial to Compare the Effectiveness of Amlodipine/Valsartan vs Hydrochlorothiazide/Telmisartan on Glucose Tolerance in Patients With Hypertension With Metabolic Syndrome","status":"COMPLETED","sponsor":"Yonsei University","startDate":"2009-04","conditions":"Hypertension","enrollment":16},{"nctId":"NCT00386607","phase":"PHASE3","title":"A Safety and Tolerability Study of the Combination of Aliskiren/Valsartan in Patients With High Blood Pressure, Followed by Long-term Safety and Tolerability of Aliskiren, Valsartan and Hydrochlorothiazide.","status":"COMPLETED","sponsor":"Novartis","startDate":"2006-10","conditions":"Hypertension","enrollment":601},{"nctId":"NCT01030458","phase":"PHASE4","title":"Newer Versus Older Antihypertensive Agents in African Hypertensive Patients (NOAAH) Trial","status":"COMPLETED","sponsor":"KU Leuven","startDate":"2010-09","conditions":"Blood Pressure","enrollment":183},{"nctId":"NCT01432106","phase":"PHASE1","title":"The Study of Novel Dual Renin Angiotensin Aldosterone System (RAAS) Blockade; Valsartan/Aliskiren in African American Patients With Hypertension and the Metabolic Syndrome","status":"WITHDRAWN","sponsor":"University of Michigan","startDate":"2011-02","conditions":"Hypertension, Metabolic Syndrome","enrollment":""},{"nctId":"NCT00239538","phase":"PHASE4","title":"SMOOTH - Blood Pressure Control in Diabetic/Obese Patients","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2003-01","conditions":"Hypertension, Diabetes Mellitus, Type 2","enrollment":840},{"nctId":"NCT00240448","phase":"PHASE4","title":"A Randomized, Double-blind, Placebo Controlled Comparison of Telmisartan Hydrochlorothiazide (HCT) and Valsartan HCT in Hypertension (HTN) Stage I/II Patients","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2003-09","conditions":"Hypertension","enrollment":1109},{"nctId":"NCT01415505","phase":"PHASE3","title":"Combination of Nebivolol and Valsartan Given as Free Tablets for Stage 1 or Stage 2 Hypertension","status":"COMPLETED","sponsor":"Forest Laboratories","startDate":"2011-08","conditions":"Hypertension","enrollment":812},{"nctId":"NCT01767259","phase":"NA","title":"Pharmacokinetic Interactions of Valsartan and Hydrochlorothiazide","status":"COMPLETED","sponsor":"Damanhour University","startDate":"2012-10","conditions":"Healthy Normotensive Participants","enrollment":24},{"nctId":"NCT01767298","phase":"NA","title":"Pharmacokinetic Interactions of Valsartan and Hydrochlorothiazide (Double Doses)","status":"COMPLETED","sponsor":"Damanhour University","startDate":"2012-10","conditions":"Healthy Normotensive Participants","enrollment":24},{"nctId":"NCT00661895","phase":"PHASE4","title":"Black Education and Treatment of Hypertension (BEAT HTN)","status":"COMPLETED","sponsor":"Creighton University","startDate":"2005-08","conditions":"Hypertension","enrollment":99},{"nctId":"NCT00902304","phase":"PHASE4","title":"Valsartan Intensified Primary Care Reduction of Blood Pressure Study","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2009-07","conditions":"Hypertension","enrollment":2337},{"nctId":"NCT01198496","phase":"PHASE4","title":"Recurrent Stroke Prevention Clinical Outcome Study","status":"UNKNOWN","sponsor":"Biomedis International Ltd.","startDate":"2010-10","conditions":"Hypertension, Stroke, Blood Pressure","enrollment":5000},{"nctId":"NCT00457483","phase":"PHASE4","title":"Nijmegen Antihypertensive Management Improvement Study","status":"COMPLETED","sponsor":"Radboud University Medical Center","startDate":"2007-08","conditions":"Primary Hypertension","enrollment":120},{"nctId":"NCT00170989","phase":"PHASE3","title":"Valsartan/Hydrochlorothiazide Combination in Hypertensive Patients Not Controlled With Valsartan Alone","status":"COMPLETED","sponsor":"Novartis","startDate":"2004-09","conditions":"Hypertension","enrollment":2714},{"nctId":"NCT00171561","phase":"PHASE4","title":"Valsartan/Hydrochlorothiazide Combination vs Amlodipine in Patients With Hypertension, Diabetes, and Albuminuria.","status":"COMPLETED","sponsor":"Novartis","startDate":"2003-03","conditions":"Hypertension","enrollment":144},{"nctId":"NCT00273299","phase":"PHASE3","title":"Valsartan/Hydrochlorothiazide Combination in the Treatment of Severe Hypertension","status":"COMPLETED","sponsor":"Novartis","startDate":"2005-11","conditions":"Hypertension","enrollment":607},{"nctId":"NCT00327587","phase":"PHASE3","title":"8-week Study to Evaluate Safety and Efficacy of Various Combinations of Valsartan, HCTZ, and Amlodipine in Patients With Moderate to Severe Hypertension","status":"COMPLETED","sponsor":"Novartis","startDate":"2006-05","conditions":"Hypertension","enrollment":2279},{"nctId":"NCT00171535","phase":"PHASE3","title":"Efficacy and Safety of Valsartan/Amlodipine Combination in Patients With Severe Hypertension","status":"COMPLETED","sponsor":"Novartis","startDate":"2004-10","conditions":"Hypertension","enrollment":130},{"nctId":"NCT00171444","phase":"PHASE4","title":"Comparison of Two Treatment Strategies in Hypertensive Patients","status":"COMPLETED","sponsor":"Novartis","startDate":"2004-06","conditions":"Hypertension","enrollment":4445},{"nctId":"NCT00171600","phase":"PHASE4","title":"Antialbuminuric Effects of Valsartan and Lisinopril","status":"TERMINATED","sponsor":"Novartis","startDate":"2005-07","conditions":"Hypertension, Early Diabetic Nephropathy","enrollment":54},{"nctId":"NCT00241007","phase":"PHASE3","title":"A Study Comparing Valsartan With And Without Hydrochlorothiazide In Patients With Hypertension","status":"COMPLETED","sponsor":"Novartis","startDate":"2003-12","conditions":"Hypertension","enrollment":836},{"nctId":"NCT00338936","phase":"PHASE3","title":"Long Term Study of VAH631 in Patients With Essential Hypertension (Extension From B1303 Study)","status":"COMPLETED","sponsor":"Novartis","startDate":"2006-05","conditions":"Hypertension","enrollment":362},{"nctId":"NCT01425411","phase":"PHASE4","title":"Effect of Valsartan on Left Ventricular Myocardial Functions in Hypertensive Patients With Left Ventricular Hypertrophy","status":"COMPLETED","sponsor":"Mustafa Kemal University","startDate":"2006-11","conditions":"Hypertension, Left Ventricular Hypertrophy","enrollment":38},{"nctId":"NCT01375322","phase":"PHASE4","title":"ADDM Study - Amtrel and Co-Diovan in Type 2 Diabetes Mellitus Hypertension Patients With Microalbuminuria","status":"COMPLETED","sponsor":"TSH Biopharm Corporation Limited","startDate":"2007-06","conditions":"Hypertension, Diabetes Mellitus, Type 2, Albuminuria","enrollment":226},{"nctId":"NCT00425997","phase":"PHASE4","title":"Efficacy of Valsartan/Hydrochlorothiazide Versus Amlodipine and Hydrochlorothiazide in Patients Hypertension","status":"COMPLETED","sponsor":"Novartis","startDate":"2006-12","conditions":"Hypertension","enrollment":480},{"nctId":"NCT00277472","phase":"PHASE4","title":"Efficacy and Safety of Valsartan/Hydrochlorothiazide Combination Therapy in Patients With Hypertension","status":"COMPLETED","sponsor":"Novartis","startDate":"2005-11","conditions":"Hypertension","enrollment":300},{"nctId":"NCT00171054","phase":"PHASE4","title":"Efficacy and Safety of Valsartan Versus Amlodipine in Postmenopausal Women With Hypertension","status":"COMPLETED","sponsor":"Novartis","startDate":"2003-09","conditions":"Hypertension","enrollment":125},{"nctId":"NCT00396656","phase":"PHASE3","title":"Safety and Efficacy of Valsartan vs Atenolol and Hydrochlorothiazide Combination on Blood Flow in Hypertensive Patients","status":"COMPLETED","sponsor":"Novartis","startDate":"2005-12","conditions":"Hypertension","enrollment":30},{"nctId":"NCT00446563","phase":"PHASE3","title":"Efficacy and Safety of Valsartan in Combination With Amlodipine Compared to Losartan Plus Hydrochlorothiazide in Patients With Hypertension and Left Ventricular Hypertrophy","status":"COMPLETED","sponsor":"Novartis","startDate":"2007-03","conditions":"Hypertension; Hypertrophy, Left Ventricular","enrollment":90},{"nctId":"NCT00698646","phase":"PHASE4","title":"Efficacy and Safety of Valsartan/Hydrochlorothiazide Combination Compared to Valsartan Monotherapy or Hydrochlorothiazide Monotherapy in Elderly (>70) With Mild-moderate Hypertension.","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2008-04","conditions":"Hypertension","enrollment":384},{"nctId":"NCT00670787","phase":"PHASE3","title":"Combination Pill of Losartan Potassium and Hydrochlorothiazide for Improvement of Medication Compliance Trial","status":"COMPLETED","sponsor":"Kyushu University","startDate":"2008-06","conditions":"Hypertension","enrollment":207},{"nctId":"NCT00931710","phase":"PHASE4","title":"Valsartan/Amlodipine As Compared to Losartan Treatment in Stage 2 Systolic Hypertension","status":"COMPLETED","sponsor":"Novartis","startDate":"2009-07","conditions":"Stage 2 Systolic Hypertension","enrollment":488},{"nctId":"NCT00280540","phase":"PHASE4","title":"Efficacy and Safety of Valsartan/Hydrochlorothiazide Combination Therapy in Patients With Hypertension","status":"COMPLETED","sponsor":"Novartis","startDate":"2005-12","conditions":"Hypertension","enrollment":648},{"nctId":"NCT00548067","phase":"PHASE3","title":"Pharmacokinetic Drug Interaction Study Following Co-administration of Valsartan, Hydrochlorothiazide and Amlodipine in Patients With Hypertension","status":"COMPLETED","sponsor":"Novartis","startDate":"2007-09","conditions":"Hypertension","enrollment":111},{"nctId":"NCT00500604","phase":"PHASE4","title":"Efficacy of Irbesartan/Hydrochlorothiazide Versus Valsartan/Hydrochlorothiazide in Mild to Moderate Hypertension","status":"COMPLETED","sponsor":"Sanofi","startDate":"2007-07","conditions":"Hypertension","enrollment":1617},{"nctId":"NCT00424801","phase":"NA","title":"Effects of Intensive Long-Term Vasodilation in Hypertensive Patients With Microvascular Angina Pectoris","status":"TERMINATED","sponsor":"University of Aarhus","startDate":"2007-01","conditions":"Microvascular Angina, Hypertension","enrollment":10},{"nctId":"NCT00687206","phase":"PHASE4","title":"Efficacy and Safety of Valsartan Plus Hydrochlorothiazide in Patients With Slight Hypertension and Target Organ Damage","status":"COMPLETED","sponsor":"Federico II University","startDate":"2008-03","conditions":"Hypertension, Ventricular Remodeling, Erectile Dysfunctions","enrollment":20},{"nctId":"NCT00426478","phase":"PHASE4","title":"Safety and Efficacy of Valsartan Plus Hydrochlorothiazide and Amlodipine in Hypertensive Patients","status":"COMPLETED","sponsor":"Novartis","startDate":"2006-11","conditions":"Hypertension","enrollment":80},{"nctId":"NCT00400777","phase":"PHASE4","title":"Efficacy and Safety of Valsartan, Hydrochlorothiazide and Amlodipine Combination Therapy in Hypertension","status":"COMPLETED","sponsor":"Novartis","startDate":"2006-08","conditions":"Hypertension","enrollment":460},{"nctId":"NCT00487123","phase":"PHASE4","title":"Efficacy of the New Closure Device in Improving Patient Compliance in Treatment of Hypertension With Valsartan+/-Hydrochlorothiazide (HCTZ) at 6 Months","status":"COMPLETED","sponsor":"Novartis","startDate":"","conditions":"Hypertension","enrollment":""},{"nctId":"NCT00684489","phase":"NA","title":"Renin-Guided Therapeutics in the Management of Untreated, Uncontrolled, or Complicated Hypertension","status":"COMPLETED","sponsor":"Medical University of South Carolina","startDate":"2003-09","conditions":"Hypertension","enrollment":52}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":102,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"VALSARTAN, VALSARTAN+HYDROCHLOROTHIAZIDE","genericName":"VALSARTAN, VALSARTAN+HYDROCHLOROTHIAZIDE","companyName":"Novartis","companyId":"novartis","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Valsartan blocks angiotensin II receptors to relax blood vessels and lower blood pressure; the combination with hydrochlorothiazide adds a diuretic to enhance sodium and water excretion. Used for Hypertension, Heart failure with reduced ejection fraction, Post-myocardial infarction with left ventricular dysfunction.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}